Validation of a detector-response correction model for in vivo dosimetry in high-dose-rate prostate brachytherapy.
BACKGROUND High-dose-rate brachytherapy (HDRBT) is an established treatment for localized prostate cancer. Despite its efficacy, HDRBT can exhibit dosimetric discrepancies between planned and delivered doses. In vivo dosimetry (IVD) using metal-oxide-semiconductor field-effect transistors (MOSFETs) enables real-time mo...